



San Francisco Monthly STD Report

Data for August, 2014
Report prepared September 26, 2014

Table 1. STDs among residents, August, 2014.

	2014		2013	
	month	YTD	month	YTD
Gonorrhea	306	2,061	281	1,590
Male rectal gonorrhea	79	563	102	512
Chlamydia	526	3,822	450	3,393
Male rectal chlamydia	129	901	110	788
Syphilis (adult total)	101	853	93	812
Primary & secondary	34	308	37	352
Early latent	50	414	42	350
Unknown latent	1	4	1	1
Late latent	16	127	13	109
Neurosyphilis	0	7	1	11
Congenital syphilis	0	0	0	0
PID	6	76	8	54




Figure 1. Monthly STD trends for San Francisco. Syphilis cases different scale.

Table 2. Selected STD cases and rates for San Francisco by age and race/ethnicity, 2014 through August only. Rates equal cases per 100,000 residents per year based on 2000 US Census data.

	(All races)		Asian/PI		African American		Hispanic		White	
	cases	rate	cases	rate	cases	rate	cases	rate	cases	rate
<i>All ages</i>										
Chlamydia	3,822	738.1	541	321.6	562	1,315.8	542	742.4	1,277	565.2
Gonorrhea	2,061	398.0	134	79.6	326	763.2	332	454.8	993	439.5
Early syphilis	722	139.4	56	33.3	64	149.8	129	176.7	414	183.2
<i>Under 20 yrs</i>										
Chlamydia	327	954.8	42	289.1	125	2,847.7	49	663.4	35	473.2
Gonorrhea	80	233.6	3	20.7	40	911.3	10	135.4	6	81.1
Early syphilis	3	8.8	0	0.0	1	22.8	0	0.0	1	13.5

Table 3. HIV testing among City Clinic patients, August, 2014.

	2014		2013	
	month	YTD	month	YTD
Tests	499	4,097	590	4,484
Antibody positive	3	40	3	43
Acute HIV infection	0	2	4	18

Note: All statistics are provisional until the annual report is released for the year. Morbidity is based on date of diagnosis. Totals for past months may change due to delays in reporting from labs and providers.




Figure 2. City Clinic visits by gender and orientation.




Figure 3. Average number of recent* sex partners for City Clinic visits by gender and sexual orientation. *Recall period is 3 months.

Pre-Exposure Prophylaxis (PrEP) Studies at the San Francisco Department of Public Health (SFDPH)

Oral Truvada® for PrEP was recently approved for HIV prevention, and demonstration projects (including The Demo Project at San Francisco City Clinic) are underway to evaluate its implementation in real-world settings. Meanwhile, new research is underway to test new PrEP formulations with the goal of increasing ease of use and expanding our prevention toolkit.

Bridge HIV, a clinical trials unit within the SFDPH, is now enrolling two PrEP studies, with more planned for next year. MTN-017 is the first study of a rectal microbicide (lube or gel) for HIV prevention in SF. This study is testing whether tenofovir gel is safe and acceptable when applied rectally in HIV-negative gay/bi men and transwomen. Participants will use the gel daily and before/after sex and compare it to daily oral Truvada.

Bridge HIV is also enrolling DOT-DBS to evaluate if testing dried blood spots and hair can be used to accurately measure how often people use PrEP (i.e., their adherence to the prescription). The study is looking for participants who live or work in the Civic Center area, as participation involves having brief visits at Bridge HIV for directly observed dosing.

HPTN 077 is a new study to evaluate the safety and tolerability of a long-acting, injectable PrEP medication (GSK744LA), which could help address adherence issues. Participants will begin by taking an oral pill, and if well tolerated, proceed to receive injections every 3 months. This study is expected to launch in 2015.

For more information on PrEP studies, please visit: www.bridgehiv.org or call 415-437-7485. AL/HG

Provider STD Reporting: 415-487-5555, 415-431-4628 (fax)

www.sfcityclinic.org